AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22272732 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence counseling (six 30 minute individual sessions with unlimited booster sessions)
Number of subjects: 60
Study 19149823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant plus nicotine patch (n = 369)
Number of subjects: 755
Study 19149823 — intervention group
Group type: COMPARATOR
Intervention: Rimonabant plus placebo patch (n = 366)
Number of subjects: 755
Study 19149823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant plus nicotine patch
Number of subjects: 755
Study 19149823 — intervention group
Group type: COMPARATOR
Intervention: Rimonabant only
Number of subjects: 755
Study 18565222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communication
Number of subjects: 2881
Study 18565222 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing
Number of subjects: 2881
Study 18565222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tailored print communication and telephone motivational interviewing
Number of subjects: 2881
Study 18565222 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a tailored letter after the last posttest)
Number of subjects: 2881
Study 16042027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (AD) patients
Number of subjects: 27
Study 16042027 — intervention group
Group type: COMPARATOR
Intervention: Cognitively intact age-matched controls
Number of subjects: 27
Study 16042027 — intervention group
Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 27
Study 15382410 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic therapy
Number of subjects: 56
Study 15382410 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 10071698 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mL injectate
Number of subjects: 50
Study 10071698 — intervention group
Group type: COMPARATOR
Intervention: 10-mL injectate
Number of subjects: 50
Study 10071698 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 5-mL and 10-mL injectates
Number of subjects: 50
Study 7729938 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-including regimens
Number of subjects: 0
Study 7729938 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF regimen
Number of subjects: 0
Study 7729938 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study 1904477 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan alone
Number of subjects: 726
Study 1904477 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan plus hexamethylmelamine
Number of subjects: 726
Study 1904477 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide plus doxorubicin (CA)
Number of subjects: 726
Study 1904477 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin with CA
Number of subjects: 726
Study 1904477 — intervention group
Group type: COMPARATOR
Intervention: CA without cisplatin
Number of subjects: 726
Study 7027894 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 23
Study 7027894 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 23
Study 7027894 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 23
Study 7027894 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 23
Study 31674052 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBO+ IBS-D
Number of subjects: 77
Study 31674052 — intervention group
Group type: COMPARATOR
Intervention: SIBO- IBS-D
Number of subjects: 77
Study 31112105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance
Number of subjects: 0
Study 31112105 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Number of subjects: 0
Study 31112105 — intervention group
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Number of subjects: 0
Study 28580646 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously
Number of subjects: 200
Study 28580646 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid esters (FAEs)
Number of subjects: 200
Study 26376074 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress dose hydrocortisone (tapering 7-day course)
Number of subjects: 64
Study 26376074 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64
Study 26376074 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress dose hydrocortisone
Number of subjects: 64
Study 26376074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24085766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 234
Study 24085766 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 234
Study 24085766 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 234
Study 21888669 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Number of subjects: 0
Study 21888669 — intervention group
Group type: COMPARATOR
Intervention: Clamp‐crushing technique
Number of subjects: 0
Study 19623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d alone)
Number of subjects: 0
Study 19623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Ritonavir (100 mg/d)
Number of subjects: 0
Study 19623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d)
Number of subjects: 0
Study 19623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Efavirenz (400 mg/d)
Number of subjects: 0
Study 17277393 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cancer therapies (specifics not provided)
Number of subjects: 0
Study 17277393 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0
Study 15077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone (Group A)
Number of subjects: 30
Study 15077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with continued symptomatic medication (Group B)
Number of subjects: 30
Study 15077933 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic medication followed by acupuncture (Group C)
Number of subjects: 30
Study 15077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Groups A and B)
Number of subjects: 30
Study 11910689 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol intravenous (i.v.) at the dose of 150 micrograms.kg‐1
Number of subjects: 29
Study 11910689 — intervention group
Group type: COMPARATOR
Intervention: Normal saline at 0.9% (control group)
Number of subjects: 29
Study 9151051 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated drains
Number of subjects: 51
Study 9151051 — intervention group
Group type: COMPARATOR
Intervention: Non-coated drains
Number of subjects: 51
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of eggs or fresh vegetables
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial body mass index (BMI)
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cancer in parents or siblings
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 29584
Study 7960367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of pickled vegetables or mouldy foods
Number of subjects: 29584
Study 2979286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg b.d. for 4 weeks
Number of subjects: 127
Study 2979286 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 127
Study 2979286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 127
Study 2979286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 30527153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 32
Study 30527153 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 26252788 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib 300 mg once daily
Number of subjects: 31
Study 26252788 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib 400 mg once daily
Number of subjects: 31
Study 26252788 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib 500 mg once daily
Number of subjects: 31
Study 23337693 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (dose not specified)
Number of subjects: 597
Study 21174055 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial therapy
Number of subjects: 99
Study 21174055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orofacial therapy)
Number of subjects: 99
Study 18438561 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + phosphoric acid etching
Number of subjects: 0
Study 18438561 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid etching
Number of subjects: 0
Study 18438561 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser alone
Number of subjects: 0
Study 16567772 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PET followed by histologic/cytologic verification of lesions
Number of subjects: 465
Study 16567772 — intervention group
Group type: COMPARATOR
Intervention: Traditional work-up (TWU) according to international guidelines
Number of subjects: 465
Study 12588381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon version of the CDLQI
Number of subjects: 101
Study 12588381 — intervention group
Group type: COMPARATOR
Intervention: Written version of the CDLQI
Number of subjects: 101
Study 12588381 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal CDLQI (cartoon version)
Number of subjects: 101
Study 12588381 — intervention group
Group type: COMPARATOR
Intervention: Postal CDLQI (written version)
Number of subjects: 101
Study 10553838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 STIM: 24 patients received a single injection of 20 mL of a mixture of 2% lidocaine and 0.5% bupivacaine with 1:200,000 epinephrine.
Number of subjects: 50
Study 10553838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 STIM: 26 patients received 10 mL of the same solution injected after stimulation of each sciatic nerve component.
Number of subjects: 50
Study 10553838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 STIM (two stimulations)
Number of subjects: 50
Study 8706233 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling by lactation counsellors
Number of subjects: 250
Study 8706233 — intervention group
Group type: COMPARATOR
Intervention: Routine group health education
Number of subjects: 250
Study 1677903 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine administered orally
Number of subjects: 7
Study 1677903 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine administered sublingually
Number of subjects: 7
Study 1677903 — intervention group
Group type: COMPARATOR
Intervention: 10 mg cetirizine administered orally or sublingually
Number of subjects: 7
Study 6337608 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg imipramine
Number of subjects: 45
Study 6337608 — intervention group
Group type: COMPARATOR
Intervention: 60 mg mianserin
Number of subjects: 45
Study 6337608 — intervention group
Group type: COMPARATOR
Intervention: 150 mg nomifensine
Number of subjects: 45
Study 6337608 — intervention group
Group type: COMPARATOR
Intervention: desipramine
Number of subjects: 45
Study 30487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient Sleep (SS)
Number of subjects: 8
Study 30487023 — intervention group
Group type: COMPARATOR
Intervention: Sleep Restriction (SR)
Number of subjects: 8
Study 26541814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 571
Study 26541814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Number of subjects: 571
Study 26541814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 0.75 mg/day
Number of subjects: 571
Study 26541814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 25047139 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 250 mg
Number of subjects: 12
Study 25047139 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 250 mg with Rifampin 600 mg QD
Number of subjects: 12
Study 25047139 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax with Rifampin
Number of subjects: 12
Study 22951358 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion in combination with low dose eptifibatide infusion
Number of subjects: 17
Study 22951358 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion + eptifibatide
Number of subjects: 17
Study 22951358 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 17
Study 19944608 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented low-Dye (ALD) taping
Number of subjects: 28
Study 19944608 — intervention group
Group type: COMPARATOR
Intervention: No-tape control
Number of subjects: 28
Study 19944608 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ALD taping and control
Number of subjects: 28
Study 18292851 — intervention group
Group type: EXPERIMENTAL
Intervention: Short individualized educational intervention program based on Prochaska's transtheoretical model for six months
Number of subjects: 38
Study 18292851 — intervention group
Group type: COMPARATOR
Intervention: Standard educational intervention
Number of subjects: 38
Study 18292851 — intervention group
Group type: EXPERIMENTAL
Intervention: Short individualized educational intervention program
Number of subjects: 38
Study 18292851 — intervention group
Group type: COMPARATOR
Intervention: Short individualized educational intervention program and standard educational intervention
Number of subjects: 38
Study 15657372 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 40
Study 15657372 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 40
Study 12635062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg/kg/min
Number of subjects: 141
Study 12635062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg/kg/min
Number of subjects: 141
Study 12635062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 microg/kg/min
Number of subjects: 141
Study 12635062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (all doses)
Number of subjects: 141
Study 10981888 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-eradicate
Number of subjects: 500
Study 10981888 — intervention group
Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 500
Study 8825533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg tablets on the night before and the morning of surgery, plus isotonic saline 0.3 ml iv before surgery ended.
Number of subjects: 60
Study 8825533 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.75 mg iv injected before the operation ended.
Number of subjects: 60
Study 8825533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 60
Study 1408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Special health care program (experimental group)
Number of subjects: 243
Study 1408861 — intervention group
Group type: COMPARATOR
Intervention: Routine well-baby care (control group)
Number of subjects: 243
Study 3936140 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (200 mg/day for 9 days)
Number of subjects: 18
Study 3936140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30854590 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular YAG laser anterior capsulotomy
Number of subjects: 66
Study 30854590 — intervention group
Group type: COMPARATOR
Intervention: Radial YAG laser anterior capsulotomy
Number of subjects: 66
Study 29258868 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack meal followed by exercise session (SE)
Number of subjects: 21
Study 29258868 — intervention group
Group type: COMPARATOR
Intervention: Snack meal only (SO)
Number of subjects: 21
Study 25348726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 97
Study 25348726 — intervention group
Group type: COMPARATOR
Intervention: Control (no HOT)
Number of subjects: 97
Study 24884672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical aiming task in patients with tension-type headache
Number of subjects: 0
Study 24884672 — intervention group
Group type: COMPARATOR
Intervention: Cervical aiming task in healthy participants
Number of subjects: 0
Study 22044116 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional braces
Number of subjects: 42
Study 22044116 — intervention group
Group type: COMPARATOR
Intervention: Nickel-free braces
Number of subjects: 42
Study 20969809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme for osteoarthritis
Number of subjects: 0
Study 18218179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 mcg twice daily for 4 weeks, then 10 mcg thereafter)
Number of subjects: 1047
Study 18218179 — intervention group
Group type: COMPARATOR
Intervention: Insulin analogue therapy (glargine or biphasic insulin aspart)
Number of subjects: 1047
Study 15721095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5710
Study 15721095 — intervention group
Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibition
Number of subjects: 5710
Study 15721095 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 5710
Study 12678187 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Number of subjects: 160
Study 12678187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10789879 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg smoked cocaine
Number of subjects: 8
Study 10789879 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (conditioned stimulus paired with cocaine)
Number of subjects: 8
Study 10789879 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ alone during extinction trials
Number of subjects: 8
Study 10789879 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoked cocaine (CS‐)
Number of subjects: 8
Study 8640708 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 to 34 mCi of 131 I (30 +/- 1.5)
Number of subjects: 149
Study 8640708 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 to 64 mCi of 131 I (50.6 +/- 5.4)
Number of subjects: 149
Study 8640708 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 to 119 mCi of 131 I (88.6 +/- 14)
Number of subjects: 149
Study 8640708 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 to 200 mCi of 131 I (155 +/- 28.7)
Number of subjects: 149
Study 1495889 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg adinazolam mesylate immediate-release (CT) tablets
Number of subjects: 31
Study 1495889 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release (SR) tablets
Number of subjects: 31
Study 1495889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1495889 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg CT tablets every 8 hr
Number of subjects: 31
Study 1495889 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg SR tablets every 12 hr
Number of subjects: 31
Study 3831144 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 34
Study 3831144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 34
Study 3831144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30661944 — intervention group
Group type: EXPERIMENTAL
Intervention: TiO2 abutment surface
Number of subjects: 15
Study 30661944 — intervention group
Group type: COMPARATOR
Intervention: Standard abutment surface
Number of subjects: 15
Study 30105400 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily teriparatide injection (20-μg)
Number of subjects: 43
Study 30105400 — intervention group
Group type: COMPARATOR
Intervention: Weekly teriparatide injection (56.5-μg)
Number of subjects: 43
Study 27144848 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral cholera vaccine Shanchol
Number of subjects: 204700
Study 27144848 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 204700
Study 25151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol MVA85A
Number of subjects: 24
Study 25151225 — intervention group
Group type: COMPARATOR
Intervention: Intravenous MVA85A
Number of subjects: 24
Study 22336292 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise intervention (n = 60)
Number of subjects: 180
Study 22336292 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise intervention (n = 60)
Number of subjects: 180
Study 22336292 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 60)
Number of subjects: 180
Study 20131030 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Decoction (YQYYD) with conventional therapy of Western medicine
Number of subjects: 108
Study 20131030 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy of Western medicine
Number of subjects: 108
Study 17542349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarizotan 5-25 mg single doses
Number of subjects: 83
Study 17542349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarizotan 10 and 20 mg b.i.d. multiple doses
Number of subjects: 83
Study 17542349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarizotan 5 mg b.i.d. multiple doses
Number of subjects: 83
Study 19385450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervico-thoracic sympathectomy
Number of subjects: 48